 Immunoglobulin Fc Fragments
"Immunoglobulin Fc Fragments" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
| Descriptor ID |
D007141
|
| MeSH Number(s) |
D12.644.541.500.697 D12.776.124.486.485.538.500 D12.776.124.486.485.680.697 D12.776.124.790.651.538.500 D12.776.124.790.651.680.660 D12.776.377.715.548.538.500 D12.776.377.715.548.680.660
|
| Concept/Terms |
Immunoglobulin Fc Fragments- Immunoglobulin Fc Fragments
- Fc Fragments, Immunoglobulin
- Immunoglobulins, Fc Fragment
- Fc Fragment Immunoglobulins
- Fragment Immunoglobulins, Fc
- Immunoglobulin Fc Fragment
- Fc Fragment, Immunoglobulin
- Immunoglobulins, Fc
- Fc Fragments
- Fc Immunoglobulins
|
Below are MeSH descriptors whose meaning is more general than "Immunoglobulin Fc Fragments".
Below are MeSH descriptors whose meaning is more specific than "Immunoglobulin Fc Fragments".
This graph shows the total number of publications written about "Immunoglobulin Fc Fragments" by people in this website by year, and whether "Immunoglobulin Fc Fragments" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 1 | 1 | 2 | | 2015 | 5 | 0 | 5 | | 2016 | 1 | 0 | 1 | | 2017 | 2 | 0 | 2 | | 2020 | 1 | 2 | 3 | | 2021 | 2 | 1 | 3 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunoglobulin Fc Fragments" by people in Profiles.
-
Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-P?rez M, Bismuth E, Dib S, Cho JI, Cox D. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. N Engl J Med. 2022 08 04; 387(5):433-443.
-
Lakhani NJ, Chow LQM, Gainor JF, LoRusso P, Lee KW, Chung HC, Lee J, Bang YJ, Hodi FS, Kim WS, Santana-Davila R, Fanning P, Squifflet P, Jin F, Kuo TC, Wan HI, Pons J, Randolph SS, Messersmith WA. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 12; 22(12):1740-1751.
-
Takeda K, Kim SH, Joetham A, Petrache I, Gelfand EW. Therapeutic benefits of recombinant alpha1-antitrypsin IgG1 Fc-fusion protein in experimental emphysema. Respir Res. 2021 Jul 16; 22(1):207.
-
Freyn AW, Han J, Guthmiller JJ, Bailey MJ, Neu K, Turner HL, Rosado VC, Chromikova V, Huang M, Strohmeier S, Liu STH, Simon V, Krammer F, Ward AB, Palese P, Wilson PC, Nachbagauer R. Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020 Sep; 45 Suppl 1:43-60.
-
Dotan E, Cardin DB, Lenz HJ, Messersmith W, O'Neil B, Cohen SJ, Denlinger CS, Shahda S, Astsaturov I, Kapoun AM, Brachmann RK, Uttamsingh S, Stagg RJ, Weekes C. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Clin Cancer Res. 2020 10 15; 26(20):5348-5357.
-
DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V. Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. J Clin Endocrinol Metab. 2020 02 01; 105(2).
-
Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, Brachmann RK, Smith DC. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Dec 15; 23(24):7490-7497.
-
Singh SM, Bandi S, Jones DNM, Mallela KMG. Effect of Polysorbate 20 and Polysorbate 80 on the Higher-Order Structure of a Monoclonal Antibody and Its Fab and Fc Fragments Probed Using 2D Nuclear Magnetic Resonance Spectroscopy. J Pharm Sci. 2017 12; 106(12):3486-3498.
-
Yung LM, Nikolic I, Paskin-Flerlage SD, Pearsall RS, Kumar R, Yu PB. A Selective Transforming Growth Factor-? Ligand Trap Attenuates Pulmonary Hypertension. Am J Respir Crit Care Med. 2016 11 01; 194(9):1140-1151.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|